Hillstream BioPharma to Present at the Tenth Annual BioNJ BioPartnering Virtual Conference

Bridgewater, New Jersey, October 1, 2020 – Hillstream BioPharma Inc. (“Hillstream”) today announced its participation at the Tenth Annual BioNJ BioPartnering Virtual Conference.  Hillstream will be providing updates on recent corporate developments as well as outlining near-term activities anticipated in Q4-2020 and early 2021.  Details about the conference are as follows:

“We are pleased to have Hillstream selected as one of our Company Presenters at BioNJ’s Virtual BioPartnering Conference and look forward to learning about the company’s progress. BioNJ’s mission is to help our Members help Patients. We are proud of the work being done by Hillstream on behalf of Patients,” said Debbie Hart, President and Chief Executive Officer of BioNJ. “The goal of the Conference is to provide emerging companies with a platform to gain visibility among and build relationships with the life sciences and investment communities in New Jersey and beyond. Because our Conference platform is now virtual, life sciences professionals from all over the world can easily participate and learn more about what New Jersey companies have to offer.”

“Hillstream is honored to be part of the BioNJ BioPartnering Virtual Conference.  As a member of BioNJ and recurring presenter, we look forward to keeping the regional investment and scientific community appraised of our progress,” stated Randy Milby, President and CEO of Hillstream.

One-on-one meetings can be arranged through the conference’s BioPartnering 1:1 virtual meeting feature.  A replay of the Hillstream’s presentation will be available to registered attendees until November 7, 2020.  Investors wishing to virtually connect with Hillstream outside of the conference can book appointments directly through Hillstream’s investor relations representative, Jennifer K. Zimmons, Ph.D. jzimmons@zimmonsic.com or +1.917.214.3514.

About Hillstream BioPharma, Inc.

Hillstream BioPharma Inc. (“Hillstream”) is a development-stage company focused on rare cancers.  By harnessing a weakness in tumors to preferentially concentrate advancing novel immune-oncology therapeutics for critical unmet needs.  By harnessing a weakness in tumors to preferentially concentrate Hillstream’s QUATRAMER™ technology, we are developing targeted cancer therapies.  The Company is advancing lead candidates, including novel small molecules and proprietary DNA expression vectors which encode inflammatory cytokines directly into tumor’s genome.  Hillstream is working to improve the lives of patients and rapidly move into the clinic to treat small cell lung cancer, soft tissue sarcoma and other unmet need rare cancers.  For more information, please visit hillstreambio.com.

About BioNJ

BioNJ is the life sciences trade association for New Jersey with nearly 400 Member companies representing research-based life sciences organizations and stakeholders across the ecosystem from the largest biopharmaceutical companies to early stage start-ups. BioNJ is dedicated to ensuring a vibrant ecosystem where Science is Supported, Companies are Created, Drugs are Developed and Patients are Paramount. Because Patients Can’t Wait®, BioNJ supports its Members in the discovery, development and commercialization of therapies and cures that save and improve lives and lessen the burden of illness and disease to society by driving capital formation, fostering entrepreneurship, advocating for public policies that advance medical innovation, providing access to talent and education and offering a cost-saving array of critical commercial resources. For more information about BioNJ, please visit www.bionj.org.

Forward Looking Statements
This press release includes forward-looking statements including, but not limited to, statements related to the development of drug candidates, our operations and business strategy, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties, including, among others, those related to our ability to obtain additional capital on favorable terms to us, or at all, including, without limitation, to fund our current and future preclinical studies and clinical trials and the success, timing and cost of our drug development program and our ongoing or future preclinical studies and clinical trials, including, without limitation, the possibility of unfavorable new clinical and preclinical data and additional analyses of existing data, as well as the risks that prior clinical and preclinical results may not be replicated. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.

Hillstream BioPharma, Inc.
Randy Milby
President & CEO
Hillstream Biopharma Inc.
Tel: +1 302.743.2995
Email: rmilby@hillstreambio.com

Investor Contact
Jennifer K. Zimmons, Ph.D.

Investor Relations
Zimmons International Communications, Inc.
Tel: +1 917.214.3514
Email: jzimmons@zimmonsic.com

Source: Hillstream BioPharma, Inc.